Pomegranate (Punica Granatum)
Pomegranate is being studied as juice, extract, peel powder and seed oil; human studies show above all a lowering of blood pressure, while findings for blood lipids and oral health are inconsistent.
We evaluated 246 human studies on Pomegranate (Punica granatum), including 125 randomised controlled trials and 37 meta-analyses or systematic reviews; the controlled studies include 6,340 participants in total. As of 24 October 2026.
1. What Is Pomegranate (Punica Granatum)? Occurrence, Origin and Forms
The pomegranate is the fruit of the pomegranate tree (Punica granatum) in the loosestrife family. The tree grows in warm, dry climates; the arils and juice serve as food, while the peel and rind have traditionally been used in preparations. In studies, juice, fruit extract, peel extract and seed oil are examined separately.
The tree is cultivated in warm regions of Asia, the Mediterranean, North Africa and the Americas, and the fruits ripen in autumn. What is processed above all is the juice from the arils, along with the peel and seeds left over from juice production.
Juice is pressed from the arils, extracts are obtained from whole fruits or from the peel and standardised to polyphenols such as punicalagin, and seed oil is pressed from the seeds. What is studied in humans is mainly juice, capsule and powder extracts, peel extracts and, less often, seed oil.
Forms and Preparations Studied
- Juice
- Whole-fruit extract
- Peel and rind extract
- Seed oil
- Fresh fruit and arils
- Powder from dried peel
Not covered on this page:
- Fruit juice blends, sweets and drinks in which pomegranate appears only as a flavouring, colouring or additive.
- Ellagic acid and punicalagin from other sources such as strawberries or walnuts.
- Other species of the genus Punica, such as Punica protopunica.
2. What Does Pomegranate (Punica Granatum) Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Blood Pressure and Blood Vessels | mixed | high | 8 meta-analyses · 33 controlled · 18 other | 1,249 |
| Blood Lipids | mixed | high | 6 meta-analyses · 18 controlled · 11 other | 728 |
| Exercise and Recovery | mixed | high | 5 meta-analyses · 13 controlled · 9 other | 374 |
| Oral and Gum Health | mixed | low | 0 meta-analyses · 22 controlled · 6 other | 1,563 |
| Prostate | mostly no difference | unclear | 1 meta-analyses · 4 controlled · 8 other | 276 |
| Other investigations | mixed | high | 16 meta-analyses · 84 controlled · 62 other | 3,862 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Pomegranate (Punica Granatum), Blood Pressure and Blood Vessels: Human Studies
Pomegranate juice lowered blood pressure more than the control in several controlled studies, for example in diabetes, dialysis, metabolic syndrome and in healthy people 538898108133. Pomegranate extracts, including peel extract, also lowered it compared with placebo 109166; in dialysis patients the difference was not confirmed after accounting for baseline values 125. A meta-analysis of randomized studies with various pomegranate forms found a lowering of systolic and diastolic blood pressure, with strongly inconsistent individual studies 24. After a single intake of pomegranate extract, blood flow and diameter of the arm artery during exercise increased more than under placebo 151152. Pulse wave velocity remained unchanged under juice 98, and pomegranate and grape juice improved flow-mediated dilation equally in adolescents 135. In dialysis patients, the vessel wall of the carotid artery developed more favorably under juice than under placebo 54; two methodological papers also found a difference in a further study with new ultrasound measures 50168. In a larger study, however, intima-media thickness remained without a difference 178. In coronary heart disease, juice reduced exercise-induced reduced blood flow to the heart muscle 105, and in unstable angina in hospital it reduced angina symptoms 173. Reviews of berry, grape and nut products do not allow a statement about pomegranate alone 3441.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Mohammadi et al. 2025 | meta-analysis · 2,306 participants | Pomegranate supplementation (PO); vs. Control/placebo groups | Diastolic blood pressure: improved (SMD: -0.39 mmHg, 95 % CI: -0.59, -0.18; P < 0.001); Systolic blood pressure: improved (SMD: -0.49 mmHg, 95 % CI: -0.68, -0.31; P < 0.001) |
| 11 Gbinigie et al. 2017 | systematic review · 619 participants | Pomegranate juice or capsules; vs. Control | Systolic blood pressure: unclear; Diastolic blood pressure: unclear (p = .038, p < .001) |
| 13 Wang et al. 2020 | meta-analysis · 572 participants | Pomegranate juice supplementation; vs. Placebo | E-selectin: no difference (WMD: 8.42 ng/mL, 95 % CI: -22.9, 39.8, P = 0.599); ICAM: no difference (WMD= -17.38 ng/mL, 95 % CI: -53.43, 18.66, P = 0.107); VCAM: no difference (WMD: -69.32 ng/mL, 95 % CI: -229.26, 90.61, P = 0.396) |
| 24 Bahari et al. 2024 | meta-analysis | Pomegranate in various forms; vs. Control/placebo | Systolic blood pressure: improved (WMD: -7.87 mmHg; 95% CI: -10.34 to -5.39; p < 0.001); Diastolic blood pressure: improved (WMD: -3.23 mmHg; 95% CI: -5.37 to -1.09; p = 0.003) |
| 27 Rossi et al. 2024 | systematic review | 100% fruit and vegetable juices, including pomegranate juice | blood pressure and vascular function: improved |
| 30 Mokgalaboni et al. 2023 | review | Pomegranate and its derivatives (forms not individually specified) | Endothelial function: improved |
| 32 Laurindo et al. 2022 | systematic review | Pomegranate (Punica granatum L.), various forms | blood pressure: improved |
| 33 Copetti et al. 2022 | systematic review | Fruit-derived anthocyanins, including pomegranate (n=2); 18 to 552 mg anthocyanins per day; acute intake to 20 days; vs. not reported | Vascular function: improved |
Further studies in this area: 34 41 42 43 45 50 53 54 57 62 71 88 95 98 105 108 109 113 125 127 133 135 143 144 145 147 148 151 152 153 154 156 159 164 166 171 172 173 178 189 206 213 217 218 225 231 234 237 241 244 247
Pomegranate (Punica Granatum) and Blood Lipids: Human Studies
In adults with metabolic diseases or dialysis, juice or extract lowered triglycerides and increased HDL cholesterol in several controlled studies 53108109113. Pomegranate extracts, including peel extract, also lowered total cholesterol more than placebo 104109166; LDL cholesterol did not fall in one of these studies 109. The evidence is high, but the results are inconsistent. The forms studied were mainly pomegranate juice, whole-fruit extract in capsules as well as peel and bark extract; the findings apply in each case only to the form and preparation tested. A meta-analysis of randomized studies, by contrast, found no effect on blood lipids 14, as did studies with juice or seed oil 7088. Under concentrated juice, LDL cholesterol rose more than under the control 108, and in a further study triglycerides rose compared with baseline 133. Mixtures with other plant extracts or foods yielded inconsistent findings and cannot be attributed to pomegranate alone 4164. It remains open which ingredients and amounts are decisive for the effects and how the sometimes short study durations affect long-term results.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Mohammadi et al. 2025 | meta-analysis · 2,306 participants | Pomegranate supplementation (PO); vs. Control/placebo groups | Total cholesterol: improved (SMD: -0.12 mg/dL, 95 % CI: -0.24, -0.00; P = 0.04); HDL cholesterol: improved (SMD: 0.27 mg/dL, 95 % CI: 0.08, 0.47; P < 0.001); Triglycerides: no difference |
| 10 Ghaemi et al. 2026 | meta-analysis · 663 participants | Pomegranate juice; vs. Control (placebo/usual diet) | Triglycerides: improved (MD: -8.2 mg/dL); LDL cholesterol: improved (MD: -4.8 mg/dL); HDL cholesterol: improved (MD: +2.8 mg/dL) |
| 14 Sahebkar et al. 2016 | meta-analysis · 545 participants | Pomegranate consumption, mainly pomegranate juice; daily juice amount consumed (exact dose not reported); supplementation duration assessed in meta-regression; vs. placebo-controlled trials | total cholesterol, LDL-C, HDL-C, triglycerides: no difference; triglycerides vs. supplementation duration (meta-regression): improved (slope: -1.07; 95% CI: -2.03 to -0.11; p = 0.029) |
| 17 Silveira et al. 2025 | meta-analysis · 128 participants | Pomegranate juice; vs. Randomized controlled trials (control group not specified) | HDL cholesterol: improved (MD: 6.21; 95% CI: 2.43 to 10.00; p = 0.001); Triglycerides: improved (MD: -23.30; 95% CI: -45.19 to -1.42; p = 0.04); LDL cholesterol: no difference |
| 27 Rossi et al. 2024 | systematic review | 100% fruit and vegetable juices, including pomegranate juice | lipid profile: improved |
| 28 Asgary et al. 2023 | systematic review | Pomegranate supplementation as capsules or liquid; Capsules 250 mg to 250 g; liquid 10 to 500 ml; 3 weeks to 12 months; vs. Control group in randomized controlled trials | ox-LDL: no difference (not statistically significant) |
| 32 Laurindo et al. 2022 | systematic review | Pomegranate (Punica granatum L.), various forms | triglycerides: improved; total cholesterol: improved; low-density lipoprotein cholesterol: improved |
| 41 García-Conesa et al. 2018 | meta-analysis | Pomegranate as ellagitannin source, with nuts, berries, grapes/wine; vs. Placebo or control within the trials | Total cholesterol: improved; LDL-cholesterol: improved; Triglycerides: improved |
Further studies in this area: 53 62 70 87 88 102 104 108 109 113 133 144 145 147 153 156 166 171 174 200 204 207 212 223 225 241 247
Pomegranate (Punica Granatum), Exercise and Recovery: Human Studies
Compared with placebo, pomegranate extract prolonged the time to exhaustion in cyclists and runners 142152. Juice before each training session increased aerobic performance over several weeks in young adults with elevated blood pressure more than placebo 159. Review articles also see indications of faster recovery after exertion 3942. Juice lowered markers of oxidative stress after exertion compared with the control 127139. A review of juice studies sees indications of less muscle soreness and inflammation 23. For muscle soreness and strength, the results are mixed: juice alleviated muscle soreness and loss of strength in the arm flexors, but not in the leg extensors 155. In other controlled studies, there was no difference in strength, muscle soreness, or creatine kinase 121142. A network meta-analysis found less muscle soreness with pomegranate, but no advantage for strength or creatine kinase; the certainty of the evidence was low 12.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 12 Xu et al. 2026 | meta-analysis · 595 participants | Plant-derived anthocyanin- and flavanol-rich supplements, including pomegranate; Outcomes at 24, 48 and 72 hours post-exercise; vs. Placebo or control conditions | DOMS at 48 hours: improved (significantly reduced 48 h DOMS vs. the placebo node, ranking first and second); Muscle strength at 48 hours: no difference (No intervention showed a clear advantage for 48 h muscle strength); Creatine kinase at 48 hours: no difference (No intervention showed a clear advantage for 48 h ... CK) |
| 19 Silva et al. 2026 | systematic review | Polyphenol supplements, including pomegranate juice; vs. Placebo | Muscle soreness and subjective well-being: improved; Biomarkers of muscle damage, inflammation, oxidative stress: no difference; Functional recovery: unclear |
| 22 Belyani et al. 2025 | meta-analysis | Pomegranate supplementation (form not specified); vs. Control (placebo or usual diet, not specified) | Myoglobin: no difference (WMD: -1.344 ng/mL; 95% CI: -4.11, 1.42 ng/mL, P = 0.342); Creatine kinase: no difference (WMD: -11.990 U/L; 95% CI: -28.64, 4.66 U/L, P = 0.158); Lactate concentrations: no difference (WMD: -0.093 mmol/L; 95% CI: -0.39, 0.21 mmol/L, P = 0.546) |
| 23 Vitošević et al. 2025 | systematic review | Pomegranate juice (among five juices); several days around exercise; vs. other juices and controls | muscle soreness: improved; inflammatory markers: improved |
| 27 Rossi et al. 2024 | systematic review | 100% fruit and vegetable juices, including pomegranate juice | exercise performance: improved |
| 31 Canals-Garzón et al. 2022 | review | Pomegranate juice (other antioxidants: taurine, melatonin, blueberries, oats); acute intake before or during exercise session; vs. Control (placebo or usual diet, not reported) | Oxidative stress: improved |
| 33 Copetti et al. 2022 | systematic review | Fruit-derived anthocyanins, including pomegranate (n=2); 18 to 552 mg anthocyanins per day; acute intake to 20 days; vs. not reported | Oxidative stress: improved; Inflammation: improved; Muscle damage: improved |
| 35 d'Unienville et al. 2021 | meta-analysis | Polyphenol-rich foods, including pomegranate; acute and multiple-day supplementation; vs. control or placebo | endurance exercise performance: improved (SMD=0.17) |
Further studies in this area: 36 39 42 65 121 125 127 128 139 142 151 152 154 155 159 160 194 205 208
Pomegranate (Punica Granatum), Oral and Gum Health: Human Studies
For oral and gum health there are numerous controlled studies, which mainly investigated preparations of peel and bark extract, whole-fruit extract as well as individual mouthwashes, gels and chips. A systematic review sees pomegranate mouthwashes and gels as a possible alternative to conventional agents, but calls for further clinical studies 26. A pomegranate mouthwash lowered plaque and gingiva index in adolescents more than placebo 117. Compared with chlorhexidine, pomegranate mouthwashes usually lowered dental plaque and gum inflammation equally well 6990161, and in one study lowered the plaque index more 81. Against caries bacteria, chlorhexidine had a somewhat stronger effect 8690161. A chip with pomegranate extract in addition to tooth cleaning improved pocket depth and attachment more than cleaning alone 131132. A gel with pomegranate extract, by contrast, did not prevent dental plaque and gum bleeding better than a placebo gel 146. In aphthae, a pomegranate gel relieved pain and shortened healing compared with placebo 118. The findings apply in each case only to the form and preparation studied; combination preparations with further plant extracts such as Myrtus communis, Quercus brantii, Portulaca oleracea and Boswellia serrata 99, propolis 114, Piper nigrum and copper sulfate 134 or Cinnamomum cassia 185 do not allow a statement about pomegranate alone. The evidence is low: many studies are small and short, and most compared only with chlorhexidine instead of placebo.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 26 Potra et al. 2024 | review | Pomegranate extracts, mouthwashes and gels; vs. conventional synthetic pharmaceuticals | plaque reduction: improved; inhibition of harmful oral microorganisms: improved; promotion of overall oral health: improved |
| 47 Ramesh et al. 2026 | randomised controlled · 500 participants | pomegranate extract; 12 months; vs. standard oral hygiene education | caries activity (DMFT): improved (p < 0.001); salivary pH: improved (p < 0.01) |
| 55 Bhavana et al. 2023 | randomised controlled · 100 participants | Mouthwash from ethanolic Punica granatum peel extract; 1 week; vs. Woodfordia fruticosa leaf extract mouthwash | Salivary amylase: unclear (p=0.000*) |
| 56 Sujanamulk et al. 2020 | randomised controlled · 100 participants | Ethanolic Punica granatum peel extract mouthwash; 5 ml per rinse, 30 seconds, twice daily; Follow-up at 1 hour and 1 week; vs. Woodfordia fruticosa leaf extract mouthwash | Colony-forming units (CFU): unclear |
| 68 Mishra et al. 2019 | randomised controlled · 80 participants | Punica granatum mouthrinse; 31 days, washout days 16-31; vs. Terminalia chebula, Vitis vinifera, fourth group | salivary S. mutans: no difference (statistically nonsignificant); plaque score at day 16: no difference (0.12); salivary pH: no difference (statistically nonsignificant) |
| 69 Sedigh-Rahimabadi et al. 2017 | randomised controlled · 80 participants | Golnaar mouthwash from Punica granatum var pleniflora; 2 weeks, then scaling, last visit 2 weeks after scaling; vs. chlorhexidine 0.2% mouthwash | plaque index: no difference (P < .001); modified gingival index: improved (P = .039); gingival bleeding index: no difference (P < .001) |
| 81 Sasi et al. 2025 | randomised controlled · 60 participants | 30% pomegranate peel extract mouthrinse vs. 0.12% chlorhexidine mouthrinse; 10 ml rinsed twice daily; 21 days; vs. 0.12% chlorhexidine mouthrinse | Plaque index: improved (1.16 ± 0.26); Plaque index at 21 days: improved (0.79 ± 0.27); Gingival index: no difference |
| 85 Takkella et al. 2023 | randomised controlled · 60 participants | Pomegranate (Punica granatum) mouthwash; 2 weeks; vs. Henna mouthwash and distilled water | Salivary AST: unclear (p<0.001); Salivary ALT: unclear (p<0.001); Salivary LDH: unclear (p=0.002) |
Further studies in this area: 86 90 91 92 117 118 119 124 129 131 132 146 161 180 181 195 202 216 231 236
Pomegranate (Punica Granatum) and Prostate: Human Studies
In men with rising PSA after prostate cancer therapy, PSA doubling time was prolonged under pomegranate extract (POMx), but without a placebo group; the authors consider the significance unclear 51. In a placebo-controlled study, pomegranate extract did not prolong PSA doubling time more than placebo; an advantage in carriers of the MnSOD-AA genotype is considered an untested hypothesis 175. A randomized controlled study with pomegranate juice saw no change in PSA kinetics compared with a placebo drink 52. POMx tablets before surgery changed neither oxidative DNA damage and tumor markers in tissue nor serum PSA compared with placebo 74. A randomized controlled study with a mixture of pomegranate, green tea, broccoli and turmeric reports a lower median PSA rise and a lower proportion that left surveillance; this finding applies to the mixture, not to pomegranate alone 49. The evidence for an effect is unclear: the placebo-controlled studies found no advantage, and the only prolongation of PSA doubling time comes from a study without a placebo group.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Hackshaw-McGeagh et al. 2015 | systematic review · 3,418 participants | Nutritional supplement of pomegranate seed, green tea, broccoli, turmeric; vs. usual diet or placebo | disease progression or mortality: improved |
| 38 Grammatikopoulou et al. 2020 | systematic review | Pomegranate fruit extract (among other dietary factors); vs. Placebo or control in RCTs | PSA concentration: unclear |
| 51 Paller et al. 2013 | randomised controlled · 104 participants | Pomegranate extract (POMx); 1 g or 3 g POMx; up to 18 months; vs. low vs. high dose, no placebo | PSA doubling time (PSADT): unclear (from 11.9 months at baseline to 18.5 months after treatment (P < 0.001)); PSADT increase >100%: unclear (43%); declining PSA levels: unclear (13 patients (13%)) |
| 52 Stenner-Liewen et al. 2013 | randomised controlled · 102 participants | Pomegranate juice; 500 ml daily for 4 weeks, then 250 ml daily for another 4 weeks; 8 weeks; vs. Placebo beverage | PSA kinetics: no difference |
| 74 Freedland et al. 2013 | randomised controlled · 70 participants | POMx tablets (Pom Wonderful); two tablets daily; up to four weeks before surgery; vs. placebo | benign tissue 8-OHdG: no difference (16% lower benign tissue 8-OHdG (P = 0.095)); cancer pS6 kinase, NF-κB, Ki67: no difference; serum PSA changes: no difference |
| 175 Pantuck et al. 2015 | randomised controlled | Pomegranate liquid extract or pomegranate juice; vs. Placebo, double-blind, multi-institutional | PSA doubling time: no difference (P>0.05) |
| 232 Hussein et al. 2021 | review | pomegranate juice and bioactive components | prevention and treatment of prostate cancer: unclear |
| 233 Hübner et al. 2021 | review | Pomegranate (form not specified) | Prostate-specific antigen (PSA): unclear |
Further studies in this area: 235 241 243 246 248
Pomegranate (Punica Granatum): Further Outcomes in Studies
Meta-analyses of randomized studies found lower inflammation markers such as hs-CRP, IL-6 and TNF-α under pomegranate than under placebo or control 813. In type 2 diabetes, seed powder lowered fasting blood glucose and HbA1c more than placebo 87, while seed oil remained without effect 70. In fatty liver, pomegranate extracts, including peel extract, lowered weight, waist circumference and fasting blood glucose more than placebo 109166. A review of rheumatic diseases sees indications of lower disease activity, with low certainty of evidence 18. Under pomegranate extract, beneficial gut bacteria such as Faecalibacterium increased compared with placebo, while the diversity of the gut flora remained unchanged 101167. In healthy people, extract reduced the appearance of skin wrinkles compared with placebo 169. In allergic asthma, extract relieved shortness of breath and lowered eosinophils and neutrophils compared with placebo 78. Pomegranate flowers reduced heavy menstrual bleeding similarly to tranexamic acid 59. The evidence is high, but the results are mixed and distributed across very different complaints. Studied were juice, whole-fruit extract, peel and bark extract, seed oil as well as fresh fruit and seed coats, whereby results are not transferable between forms. It remains open which form and amount works optimally and how background diet has an effect.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Chen et al. 2026 | meta-analysis · 9,191 participants | herbal therapies including pomegranate; vs. various herbal interventions compared with each other | liver stiffness: improved (MD -0.86; P = .04) |
| 2 Long et al. 2023 | meta-analysis · 3,852 participants | Pomegranate extract among 15 polyphenols; vs. Placebo or usual care | Disease activity score (DAS28): improved; Inflammation markers (CRP, ESR): improved; Oxidative stress: improved |
| 4 Mohammadi et al. 2025 | meta-analysis · 2,306 participants | Pomegranate supplementation (PO); vs. Control/placebo groups | Body weight: improved (SMD: -0.14 kg, 95 % CI: -0.25, -0.03; P = 0.01); Body mass index: improved (SMD: -0.17 kg/m2, 95 % CI: -0.30, -0.04; P = 0.01); Fasting blood glucose: improved (SMD: -0.15 mg/dL, 95 % CI: -0.26, -0.04; P = 0.01) |
| 5 Mohammadzaheri et al. 2025 | meta-analysis · 1,500 participants | Pomegranate products (juice, extract); vs. Control/placebo | Fasting blood glucose (FBS): improved (WMD: -3.036 mg/dl; 95% CI, -4.273 to -1.799, P < 0.001); Insulin: improved (WMD: -0.967 IU/mL; 95% CI, -1.486 to -0.448, P < 0.001); HOMA-IR: improved (WMD: -0.338; 95% CI, -0.470 to -0.205, P < 0.001) |
| 6 Verhoog et al. 2019 | review · 1,444 participants | Pomegranate extract (among other dietary factors); vs. various dietary interventions | Abundance of Akkermansia muciniphila: improved |
| 7 Wu et al. 2025 | meta-analysis · 894 participants | Pomegranate juice (among eight polyphenols); vs. Placebo | Efficacy in COPD: no difference (did not show significant efficacy or insufficient evidence) |
| 8 Jazinaki et al. 2024 | meta-analysis · 696 participants | Pomegranate juice; under 250 ml/day in subgroups; vs. Control groups | C-reactive protein: improved (WMD: -2.55 mg/L; 95%CI: -3.44 to -1.66; p < 0.001) |
| 9 Yin et al. 2025 | meta-analysis · 673 participants | Pomegranate extracts: juice, seed oil, peel/fruit extract, peel-added bread; at least 4 weeks; vs. Placebo or treatment without pomegranate extract | HOMA-IR: no difference (WMD = -0.03, 95%CI: -0.37 to 0.31, and p = 0.851); Fasting insulin: no difference (WMD = -0.03, 95%CI: -0.42 to 0.36, and p = 0.862); QUICKI in T2DM and PCOS: no difference (WMD = 0.00, 95%CI: 0.00 to 0.01, and p = 0.002) |
Further studies in this area: 13 15 16 17 18 20 21 25 27 28 29 30 32 36 37 40 41 44 45 46 48 51 52 54 57 58 59 60 61 62 63 65 66 67 70 71 72 73 75 76 77 78 79 80 82 83 84 87 89 93 94 95 96 97 98 100 101 103 104 106 107 109 110 111 112 113 115 116 120 122 123 125 126 127 130 133 136 137 138 140 141 143 144 145 147 149 150 157 158 162 163 164 165 166 167 169 170 171 172 173 174 176 177 179 182 183 184 186 187 188 189 190 191 192 193 196 197 198 199 200 201 203 204 206 207 209 210 211 212 213 214 215 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 234 238 239 240 241 242 245
4. How Is Pomegranate (Punica Granatum) Dosed? Preparation, Dose and Duration in Studies
The studies investigated pomegranate juice, whole-fruit extract in capsules, peel and bark extract, seed oil as well as powder from dried peel and fresh seed coats. The preparations ranged from beverages to mouthrinses and gels to capsules and fortified bread. Results apply in each case only to the form and preparation tested and cannot be transferred to other forms.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| pomegranate extract | — | 12 months | 47 |
| pomegranate extract added to GnRH analog therapy | daily, amount not stated | 3 months | 48 |
| pomegranate juice or extract | — | 1 year | 50 |
| Pomegranate extract (POMx) | 1 g or 3 g POMx | up to 18 months | 51 |
| Pomegranate juice | 500 ml daily for 4 weeks, then 250 ml daily for another 4 weeks | 8 weeks | 52 |
| pomegranate juice (0.7 mM polyphenols) | 100 cc three times a week | one year | 53 |
| pomegranate juice or placebo | 100 cc three times weekly during dialysis | 1 year | 54 |
| Mouthwash from ethanolic Punica granatum peel extract | — | 1 week | 55 |
| Ethanolic Punica granatum peel extract mouthwash | 5 ml per rinse, 30 seconds, twice daily | Follow-up at 1 hour and 1 week | 56 |
| pomegranate peel tablets (225 mg PPE, 90 mg ellagic acid) and/or vitamin E soft gel (400 IU) | 2 tablets + 1 soft gel daily | 8 weeks | 57 |
| Pomegranate juice 8 oz vs. placebo | 8 oz daily | from enrollment to delivery | 58 |
| Persian Golnar (pomegranate flower) | — | 5 days from day 1 of menses for 3 cycles | 59 |
| Synbiotic pomegranate juice (SPJ) vs. pomegranate juice (PJ) vs. synbiotic beverage (SB) vs. placebo | 2 L weekly | — | 60 |
| Bread fortified with 3.5% pomegranate peel powder | 3.5% pomegranate peel powder in bread | 12 weeks | 61 |
| Bread fortified with 3.5% pomegranate peel powder | 100 g bread per day | — | 62 |
5. Is Pomegranate (Punica Granatum) Safe? Side Effects in Studies
The studies report predominantly no or only mild adverse events. In a study with pomegranate extract, diarrhea occurred more frequently under the higher dose than under the lower one 51. In pregnant women with juice, fetal cardiac ultrasound in an examined subgroup showed no constriction of the ductus arteriosus 58. Long-term safety is not established for peel extracts 26.
| Study | Reported side effects |
|---|---|
| 2 Long et al. 2023 | Adding polyphenols did not increase adverse events |
| 9 Yin et al. 2025 | no adverse reactions reported |
| 11 Gbinigie et al. 2017 | No adverse events observed |
| 18 de et al. 2026 | no serious adverse events reported |
| 26 Potra et al. 2024 | long-term safety not established |
| 42 Ammar et al. 2018 | not reported |
| 51 Paller et al. 2013 | Diarrhea 1.9% (1 g) and 13.5% (3 g) |
| 52 Stenner-Liewen et al. 2013 | No grade 3 or higher toxicities |
| 58 Ross et al. 2021 | no evidence of ductal constriction on fetal echocardiogram |
| 69 Sedigh-Rahimabadi et al. 2017 | no staining effect with Golnaar |
| 74 Freedland et al. 2013 | well tolerated, no treatment-related withdrawals |
| 76 Reisi-Vanani et al. 2025 | no significant differences in adverse effects |
6. What Remains Open: Limits of the Evidence
- The optimal form, amount and duration of pomegranate intake is unclear.
- Many studies are small and short, which limits generalizability.
- Combination products with other plant extracts do not allow conclusions about pomegranate alone.
- The role of background diet and other foods of the participants is not sufficiently studied.
- For peel extract and seed oil, controlled studies are lacking in some areas.
7. Bottom Line: What Is Established About Pomegranate (Punica Granatum)
In human studies, pomegranate preparations above all lowered blood pressure; findings for blood lipids, vascular function and oral health are inconsistent. For blood pressure and blood lipids the evidence is high, for oral health low, because most studies compared only with chlorhexidine. However, the results differ depending on form and preparation, and not all studies find improvements. In prostate cancer, pomegranate did not change the PSA course compared with placebo, and in sports the findings are mixed. Combination preparations make it difficult to attribute the effect to pomegranate alone. Open questions concern the optimal form, amount and long-term effect.
Frequently Asked Questions
How well has Pomegranate (Punica granatum) been studied in humans?
We evaluated 246 human studies on Pomegranate (Punica granatum), including 125 randomised controlled trials and 37 meta-analyses or systematic reviews; the controlled studies include 6,340 participants in total. As of 24 October 2026.
Does Pomegranate (Punica granatum) help with blood Pressure and Blood Vessels? What the studies show
Does Pomegranate (Punica granatum) help with blood Lipids? What the studies show
Does Pomegranate (Punica granatum) help with exercise and Recovery? What the studies show
Does Pomegranate (Punica granatum) help with oral and Gum Health? What the studies show
Does Pomegranate (Punica granatum) help with prostate? What the studies show
Which forms of pomegranate were investigated in the studies?
Investigated were mainly pomegranate juice, whole-fruit extract in capsules, peel and bark extract, seed oil as well as powder from dried peel and fresh seed coats. The studies examined these forms separately from one another. Results cannot be transferred from one form to another.
Do human studies show an effect on blood pressure?
Yes: pomegranate juice lowered blood pressure more than the control in several controlled studies 538898108133; a meta-analysis of randomized studies confirms this 24. After a single intake of pomegranate extract, blood flow and diameter of the brachial artery under stress increased more than under placebo 151152.
How safe is the intake of pomegranate preparations?
Are there studies on oral and gingival health?
Yes: a pomegranate mouthrinse lowered the plaque and gingiva index more than placebo 117, and compared with chlorhexidine, pomegranate mouthrinses were as good as or better 698190. A chip with pomegranate extract in addition to tooth cleaning improved pocket depth and attachment more than cleaning alone 131132. A gel with pomegranate extract, by contrast, did not prevent dental plaque and gingival bleeding better than a placebo gel 146.
Sources
- 1Chen Liang A, Cruz Castillo Y, Fermin Madera MD, Sairaj RT, Medina J, Moreno Díaz TA et al. · 2026
- 2Long Z, Xiang W, He Q, Xiao W, Wei H, Li H et al. · 2023
- 3Hackshaw-McGeagh LE, Perry RE, Leach VA, Qandil S, Jeffreys M, Martin RM et al. · 2015
- 4Mohammadi S, Heshmati J, Baziar N, Ziaei S, Farsi F, Ebrahimi S et al. · 2025
- 5Mohammadzaheri F, Sheikhhossein F, Hemmati A, Ghoreishy SM, Mohammadi-Sartang M, Shiraseb F et al. · 2025
- 6Verhoog S, Taneri PE, Roa Díaz ZM, Marques-Vidal P, Troup JP, Bally L et al. · 2019
- 7Wu D, Dong Y, Zhang D, Wang T, Ye H, Zhang W · 2025
- 8
- 9Yin S, Zhu F, Zhou Q, Chen M, Wang X, Chen Q · 2025
- 10Ghaemi F, Emadzadeh M, Almahmeed W, Jamialahmadi T, Karav S, Sahebkar A · 2026
- 11Gbinigie OA, Onakpoya IJ, Spencer EA · 2017
- 12Xu KX, Chang J, Wu YJ, Chen HW, Zheng JW, Liu C · 2026
- 13Wang P, Zhang Q, Hou H, Liu Z, Wang L, Rasekhmagham R et al. · 2020
- 14Sahebkar A, Simental-Mendía LE, Giorgini P, Ferri C, Grassi D · 2016
- 15Huang H, Liao D, Chen G, Chen H, Zhu Y · 2017
- 16Sahebkar A, Gurban C, Serban A, Andrica F, Serban MC · 2016
- 17Silveira V, Braz P, Grande AJ, Colonetti T, Rodrigues Uggioni ML, da Silveira Prestes G et al. · 2025
- 18de Carvalho JF, Hautz E · 2026
- 19Silva Díaz V, Castillo-Paredes A, Iman Torres AJ, Alves Vargas AE, Guzmán-Muñoz E, Narrea Vargas JJ · 2026
- 20Van den Bruel K, Kulyk M, Neerinckx B, De Vlam K · 2025
- 21Yu M, Liu S, Li J, Ni C, Li X, Cui W · 2025
- 22Belyani S, Kazeminasab F, Niazi M, Bagheri R, Hesari MM, Rosenkranz SK et al. · 2025
- 23Vitošević B, Filipović M, Popović L, Sterkowicz-Przybycień K, Purenović-Ivanović T · 2025
- 24Bahari H, Omidian K, Goudarzi K, Rafiei H, Asbaghi O, Hosseini Kolbadi KS et al. · 2024
- 25Morgado A, Tsampoukas G, Sokolakis I, Schoentgen N, Urkmez A, Sarikaya S · 2024
- 26Potra Cicalău GI, Vicaș LG, Ciavoi G, Ghitea TC, Csaba N, Cristea RA et al. · 2024
- 27Rossi I, Mignogna C, Del Rio D, Mena P · 2024
- 28Asgary S, Karimi R, Pour PM, Heydarpour F, Mostafaei S, Farzaei MH et al. · 2023
- 29Molani-Gol R, Foroumandi E, Alizadeh M, Kheirouri S · 2023
- 30Mokgalaboni K, Dlamini S, Phoswa WN, Modjadji P, Lebelo SL · 2023
- 31Canals-Garzón C, Canals-Garzón C, Guisado-Barrilao R, Martínez-García D, Chirosa-Ríos IJ, Jerez-Mayorga D et al. · 2022
- 32Laurindo LF, Barbalho SM, Marquess AR, Grecco AIS, Goulart RA, Tofano RJ et al. · 2022
- 33Copetti CLK, Diefenthaeler F, Hansen F, Vieira FGK, Di Pietro PF · 2022
- 34Wang Y, Gallegos JL, Haskell-Ramsay C, Lodge JK · 2021
- 35d'Unienville NMA, Blake HT, Coates AM, Hill AM, Hill AM, Nelson MJ et al. · 2021
- 36Ortega DR, López AM, Amaya HM, de la Rosa FJB · 2021
- 37Malek Mahdavi A, Javadivala Z · 2021
- 38Grammatikopoulou MG, Gkiouras K, Papageorgiou SΤ, Myrogiannis I, Mykoniatis I, Papamitsou T et al. · 2020
- 39Bongiovanni T, Genovesi F, Nemmer M, Carling C, Alberti G, Howatson G · 2020
- 40Virgen-Carrillo CA, Martínez Moreno AG, Valdés Miramontes EH · 2020
- 41García-Conesa MT, Chambers K, Combet E, Pinto P, Garcia-Aloy M, Andrés-Lacueva C et al. · 2018
- 42Ammar A, Bailey SJ, Chtourou H, Trabelsi K, Turki M, Hökelmann A et al. · 2018
- 43Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D · 2017
- 44Javan R, Yousefi M, Nazari SM, Amiri P, Mosavi-Jarrahi A, Modiramani P et al. · 2016
- 45Vlachojannis C, Erne P, Schoenenberger AW, Chrubasik-Hausmann S · 2015
- 46
- 47
- 48
- 49Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P · 2014
- 50Zhao Y, Spence JD, Chiu B · 2021
- 51Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH et al. · 2013
- 52Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T et al. · 2013
- 53Shema-Didi L, Kristal B, Sela S, Geron R, Ore L · 2014
- 54Shema-Didi L, Sela S, Ore L, Shapiro G, Geron R, Moshe G et al. · 2012
- 55Bhavana S, Nallamilli SM, Thippani M, Gundapaneni N, Sahitya Y, Keerthi Reddy V et al. · 2023
- 56Sujanamulk B, Shyam Sunder S, Ratnakar Pawar B, Rajalakshmi C, Naik Maloth K · 2020
- 57Jafari T, Fallah AA, Reyhanian A, Sarmast E · 2020
- 58Ross MM, Cherkerzian S, Mikulis ND, Turner D, Robinson J, Inder TE et al. · 2021
- 59Anti-hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double-blind, randomized controlled trialGoshtasebi A, Mazari Z, Behboudi Gandevani S, Naseri M · 2015
- 60Esmaeilinezhad Z, Babajafari S, Sohrabi Z, Eskandari MH, Amooee S, Barati-Boldaji R · 2019
- 61Zare M, Tarrahi MJ, Sadeghi O, Karimifar M, Goli SAH, Amani R · 2025
- 62Zare M, Rezaei A, Karimifar M, Tarrahi MJ, Saraf-Bank S, Goli SAH et al. · 2025
- 63Banihani SA, Makahleh SM, El-Akawi ZJ · 2020
- 64Messier H, D'Adamo CR, Panchal N, Patel G · 2026
- 65Farhat G, Malla J, Al-Dujaili EAS, Vadher J, Nayak P, Drinkwater K · 2025
- 66Rezapour M, Zahedpasha Y, Kamalinejad M, Memariani Z, Alijanpour M, Ahmadpour-Kacho M et al. · 2023
- 67Chatzikostopoulos T, Gialaouzidis M, Koutoupa A, Tsolaki M · 2024
- 68Mishra P, Marwah N, Agarwal N, Chaturvedi Y, Suohu T · 2019
- 69Sedigh-Rahimabadi M, Fani M, Rostami-Chijan M, Zarshenas MM, Shams M · 2017
- 70Faghihimani Z, Mirmiran P, Sohrab G, Iraj B, Faghihimani E · 2016
- 71Farhat G, Malla J, Vadher J, Al-Dujaili EAS · 2025
- 72Henning SM, Yang J, Lee RP, Huang J, Hsu M, Thames G et al. · 2019
- 73Farhat G, Malla J, Hanson L, Vadher J, Al-Dujaili EAS · 2025
- 74Freedland SJ, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y et al. · 2013
- 75Hou C, Shi H, Xiao J, Song X, Luo Z, Ma X et al. · 2024
- 76Reisi-Vanani V, Rahmani F, Kheiri S, Soleimani A, Bijad E, Abolhansanzadeh Z et al. · 2025
- 77Ekhlasi G, Shidfar F, Agah S, Merat S, Hosseini AF · 2015
- 78Hosseini SA, Shateri Z, Abolnezhadian F, Maraghi E, Haddadzadeh Shoushtari M, Zilaee M · 2023
- 79Shateri Z, Hosseini SA, Abolnezhadian F, Maraghi E, Haddadzadeh Shoushtari M, Zilaee M · 2022
- 80
- 81Sasi A, Mohamed SC, Mathew L, Ramesh R, Beevi N R · 2025
- 82Ikeda Y, Nasu M, Bruxer JY, Díaz-Puertas R, Martínez-Godfrey J, Bulbiankova D et al. · 2025
- 83Krishnakumar A, Chellappan DK, Jeyakodi S, Dalal M, Shetty S · 2024
- 84Rafraf M, Haghighian MK, Molani-Gol R, Hemmati S, Asghari Jafarabadi M · 2024
- 85Takkella BK, Venkata Anusha N, Lokanathan Balaji D, Prabhat MV, Sarat G, Polepalle T et al. · 2023
- 86Jacob B, Malli Sureshbabu N, Ranjan M, Ranganath A, Siddique R · 2021
- 87Seyed Hashemi M, Namiranian N, Tavahen H, Dehghanpour A, Rad MH, Jam-Ashkezari S et al. · 2021
- 88Sohrab G, Roshan H, Ebrahimof S, Nikpayam O, Sotoudeh G, Siasi F · 2019
- 89Sohrab G, Ebrahimof S, Sotoudeh G, Neyestani TR, Angoorani P, Hedayati M et al. · 2017
- 90Bansal A, Marwah N, Nigam AG, Goenka P, Goel D · 2015
- 91Menezes SM, Cordeiro LN, Viana GS · 2006
- 92Vasconcelos LC, Sampaio MC, Sampaio FC, Higino JS · 2003
- 93Leventelis C, Kampitsi A, Alexandros M, Dimitriosc K, Georgios M, Liadaki K et al. · 2026
- 94Leventelis C, Barmpas PT, Kampitsi A, Iliopoulou K, Toutouktsi N, Malakopoulos P et al. · 2025
- 95Stockton A, Farhat G, McDougall GJ, Al-Dujaili EAS · 2017
- 96Ghavipour M, Sotoudeh G, Tavakoli E, Mowla K, Hasanzadeh J, Mazloom Z · 2017
- 97
- 98Lynn A, Hamadeh H, Leung WC, Russell JM, Barker ME · 2012
- 99Talebi Ardakani M, Farahi A, Mojab F, Moscowchi A, Gharazi Z · 2022
- 100Cortés-Martín A, Iglesias-Aguirre CE, Meoro A, Selma MV, Espín JC · 2021
- 101González-Sarrías A, Romo-Vaquero M, García-Villalba R, Cortés-Martín A, Selma MV, Espín JC · 2018
- 102González-Sarrías A, García-Villalba R, Romo-Vaquero M, Alasalvar C, Örem A, Zafrilla P et al. · 2017
- 103Yousefi M, Sadriirani M, Mahmoodi S, Samimi B, Pourmahmoudi A, Hosseinikia M et al. · 2023
- 104Hosseini B, Saedisomeolia A, Wood LG, Yaseri M, Tavasoli S · 2016
- 105Sumner MD, Elliott-Eller M, Weidner G, Daubenmier JJ, Chew MH, Marlin R et al. · 2005
- 106Jafarirad S, Goodarzi R, Mohammadtaghvaei N, Dastoorpoor M, Alavinejad P · 2023
- 107Abedini M, Ramezani-Jolfaie N, Ghasemi-Tehrani H, Tarrahi MJ, Amani R · 2023
- 108Abedini M, Ghasemi-Tehrani H, Tarrahi MJ, Amani R · 2021
- 109Goodarzi R, Jafarirad S, Mohammadtaghvaei N, Dastoorpoor M, Alavinejad P · 2021
- 110Sohrab G, Angoorani P, Tohidi M, Tabibi H, Kimiagar M, Nasrollahzadeh J · 2015
- 111Effects of pomegranate juice consumption on inflammatory markers in patients with type 2 diabetes: A randomized, placebo-controlled trialSohrab G, Nasrollahzadeh J, Zand H, Amiri Z, Tohidi M, Kimiagar M · 2014
- 112Zelicha H, Yang J, Diacova T, Wang J, Pan Y, Wang S et al. · 2026
- 113Barati Boldaji R, Akhlaghi M, Sagheb MM, Esmaeilinezhad Z · 2020
- 114Maria Parro Y, de Mendonça Guimarães D, Sampaio Muller H, Barbosa Coelho E, Aparecida Berretta A, Aparecida de Lima J et al. · 2022
- 115Chan LP, Tseng YP, Liu C, Liang CH · 2022
- 116
- 117Effectiveness of Pomegranate Mouthrinse in Reducing Bacterial Plaque, Gingival Inflammation and Total Salivary Proteins over a Period of 90 Days: A Double-Blind Randomized TrialDeepak JC, Samuel SR · 2018
- 118Ghalayani P, Zolfaghary B, Farhad AR, Tavangar A, Soleymani B · 2013
- 119Somu CA, Ravindra S, Ajith S, Ahamed MG · 2012
- 120Ghoochani N, Karandish M, Mowla K, Haghighizadeh MH, Jalali MT · 2016
- 121Lamb KL, Ranchordas MK, Johnson E, Denning J, Downing F, Lynn A · 2019
- 122Nuñez-Sánchez MA, González-Sarrías A, García-Villalba R, Monedero-Saiz T, García-Talavera NV, Gómez-Sánchez MB et al. · 2017
- 123
- 124Eltay EG, Gismalla BG, Mukhtar MM, Awadelkarim MOA · 2021
- 125Wu PT, Fitschen PJ, Kistler BM, Jeong JH, Chung HR, Aviram M et al. · 2015
- 126Bookheimer SY, Renner BA, Ekstrom A, Li Z, Henning SM, Brown JA et al. · 2013
- 127Fuster-Muñoz E, Roche E, Funes L, Martínez-Peinado P, Sempere JM, Vicente-Salar N · 2016
- 128Gassner M, Bragagna L, Dasht Bayaz HH, Stumpf-Knaus C, Schlosser L, Lemberg J et al. · 2025
- 129Lavaee F, Parhizkar E, Tavakoli F, Zarshenas MM, Asmarian N · 2024
- 130Dormal V, Pachikian B, Debock E, Buchet M, Copine S, Deldicque L · 2022
- 131
- 132Tyagi P, Dodwad VW, Vaish S, Chowdhery T, Gupta N, Kukreja JB · 2020
- 133
- 134Abullais SS, Dani N, Hamiduddin, Priyanka N, Kudyar N, Gore A · 2015
- 135Hashemi M, Kelishadi R, Hashemipour M, Zakerameli A, Khavarian N, Ghatrehsamani S et al. · 2010
- 136Cerdá B, Soto C, Albaladejo MD, Martínez P, Sánchez-Gascón F, Tomás-Barberán F et al. · 2006
- 137Stockton A, Al-Dujaili EAS · 2022
- 138Banihani SA, Fashtaky RA, Makahleh SM, El-Akawi ZJ, Khabour OF, Saadeh NA · 2020
- 139Effect of pomegranate juice supplementation on matrix metalloproteinases 2 and 9 following exhaustive exercise in young healthy malesMazani M, Fard AS, Baghi AN, Nemati A, Mogadam RA · 2014
- 140Shema-Didi L, Kristal B, Ore L, Shapiro G, Geron R, Sela S · 2013
- 141Khuda F, Iqbal Z, Khan A, Zakiullah, Samiullah, Sahibzada MUK et al. · 2021
- 142Torregrosa-García A, Ávila-Gandía V, Luque-Rubia AJ, Abellán-Ruiz MS, Querol-Calderón M, López-Román FJ · 2019
- 143
- 144Kojadinovic M, Glibetic M, Vucic V, Popovic M, Vidovic N, Debeljak-Martacic J et al. · 2021
- 145Rivara MB, Mehrotra R, Linke L, Ruzinski J, Ikizler TA, Himmelfarb J · 2015
- 146Salgado AD, Maia JL, Pereira SL, de Lemos TL, Mota OM · 2006
- 147
- 148Betanzos-Cabrera G, Cabrera-García P, Fabella-Illescas HE, Valle-Mondragón LD, Talamantes-Gómez JM, Sánchez-Ortiz NA et al. · 2026
- 149González-Ortiz M, Martínez-Abundis E, Espinel-Bermúdez MC, Pérez-Rubio KG · 2011
- 150Urbaniak A, Basta P, Ast K, Wołoszyn A, Kuriańska-Wołoszyn J, Latour E et al. · 2018
- 151Roelofs EJ, Smith-Ryan AE, Trexler ET, Hirsch KR, Mock MG · 2017
- 152Trexler ET, Smith-Ryan AE, Melvin MN, Roelofs EJ, Wingfield HL · 2014
- 153Mathew AS, Capel-Williams GM, Berry SE, Hall WL · 2012
- 154Pranskuniene Z, Belousoviene E, Baranauskiene N, Eimantas N, Vaitkaitiene E, Bernatoniene J et al. · 2020
- 155Trombold JR, Reinfeld AS, Casler JR, Coyle EF · 2011
- 156Almoraie MM, Spencer JP, Wagstaff C, Jackson KG · 2026
- 157Haarhuis JE, Ahn-Jarvis J, Savva GM, Day-Walsh PE, Ferns C, Hughes S et al. · 2026
- 158Minato I, Mena P, Ricciardiello L, Scaioli E, Belluzzi A, Rotondo E et al. · 2025
- 159
- 160Tan R, Price KM, Wideen LE, Lincoln IG, Karl ST, Seals JP et al. · 2023
- 161Mahd MA, Aref P, Emadi F, Javadi F, Kharazi Fard MJ, Tavassoli-Hojjati S · 2023
- 162Anlamlert W, Sermsappasuk P · 2020
- 163Chen B, Tuuli MG, Longtine MS, Shin JS, Lawrence R, Inder T et al. · 2012
- 164Nasri K, Ghaedi F, Safi F, Latifi SA, Almasi-Hashiani A · 2025
- 165Zubair M, Ahmed A, Afzaal M, Saeed F, Faisal Z, Asghar A et al. · 2024
- 166Barghchi H, Milkarizi N, Belyani S, Norouzian Ostad A, Askari VR, Rajabzadeh F et al. · 2023
- 167Sivamani RK, Chakkalakal M, Pan A, Nadora D, Min M, Dumont A et al. · 2023
- 168Chen X, Zhao Y, Spence JD, Chiu B · 2023
- 169Chakkalakal M, Nadora D, Gahoonia N, Dumont A, Burney W, Pan A et al. · 2022
- 170Siddarth P, Li Z, Miller KJ, Ercoli LM, Merril DA, Henning SM et al. · 2020
- 171Esmaeilinezhad Z, Barati-Boldaji R, Brett NR, de Zepetnek JOT, Bellissimo N, Babajafari S et al. · 2020
- 172Sohrab G, Nasrollahzadeh J, Tohidi M, Zand H, Nikpayam O · 2018
- 173Razani Z, Dastani M, Kazerani HR · 2017
- 174Manthou E, Georgakouli K, Deli CK, Sotiropoulos A, Fatouros IG, Kouretas D et al. · 2017
- 175Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A et al. · 2015
- 176Nuñez-Sánchez MA, Dávalos A, González-Sarrías A, Casas-Agustench P, Visioli F, Monedero-Saiz T et al. · 2015
- 177Kamali M, Tavakoli H, Khodadoost M, Daghaghzadeh H, Kamalinejad M, Gachkar L et al. · 2015
- 178Davidson MH, Maki KC, Dicklin MR, Feinstein SB, Witchger M, Bell M et al. · 2009
- 179Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S · 2006
- 180DiSilvestro RA, DiSilvestro DJ, DiSilvestro DJ · 2009
- 181Mahapatra S, Hebbale M, Mhapuskar A, Halli R, Jadhav S · 2024
- 182Ahmed FE, Gouda MM, Hussein LA, Ahmed NC, Vos PW, Mohammad MA · 2017
- 183Farkas D, Oleson LE, Zhao Y, Harmatz JS, Zinny MA, Court MH et al. · 2007
- 184Abdlekawy KS, Donia AM, Elbarbry F · 2017
- 185Santana NN, Engel LA, Adamczuk MS, Assunção TA, Dalmagro M, Batisti DLS et al. · 2026
- 186Leventelis C, Makri S, Ververi A, Papageorgiou K, Tentolouri A, Mountzouridi E et al. · 2025
- 187García P, Bustamante A, Echeverría F, Encina C, Palma M, Sanhueza L et al. · 2023
- 188Long J, Guo Y, Yang J, Henning SM, Lee RP, Rasmussen A et al. · 2019
- 189Basu A, Newman ED, Bryant AL, Lyons TJ, Betts NM · 2013
- 190Allegra S, De Francia S, Turco F, Bertaggia I, Chiara F, Armando T et al. · 2023
- 191Banihani SA, Makahleh SM, El-Akawi Z, Al-Fashtaki RA, Khabour OF, Gharibeh MY et al. · 2014
- 192Thotambailu AM, Bhandary BSK, Sharmila KP · 2019
- 193Li Z, Henning SM, Lee RP, Lu QY, Summanen PH, Thames G et al. · 2015
- 194Optimized Curcumin, Pomegranate Extract, and Methylsulfonylmethane Reduce Acute, Systemic Inflammatory Response to a Half-marathon RaceTanner EA, Gary MA, Michalik S, Davis AA, McFarlin BK · 2022
- 195Vieira APM, Danelon M, Fernandes GL, Berretta AA, Buszinski AFM, Dos Santos L et al. · 2024
- 196Henning SM, Yang J, Lee RP, Huang J, Thames G, Korn M et al. · 2022
- 197V Stoecker W, Kopel J, Geria N, Nosoudi N · 2025
- 198Scionti F, Maurotti S, Mazza E, Mirarchi A, Russo R, Doria P et al. · 2025
- 199Tzekaki EE, Katsipis G, Chatzikostopoulos A, Koutoupa A, Lavrentiadou SN, Tsolaki M et al. · 2025
- 200Cortés-Martín A, Iglesias-Aguirre CE, Marín A, Romo-Vaquero M, Vallejo F, Espín JC et al. · 2024
- 201Wang YH, Mondal G, Khan W, Gurley BJ, Yates CR · 2023
- 202Chrubasik-Hausmann S, Hellwig E, Müller M, Al-Ahmad A · 2021
- 203García-Villalba R, Selma MV, Espín JC, Tomás-Barberán FA · 2019
- 204Selma MV, González-Sarrías A, Salas-Salvadó J, Andrés-Lacueva C, Alasalvar C, Örem A et al. · 2018
- 205Farzana HR, Vigriawan GE, Santini A, Nurkolis F · 2026
- 206
- 207
- 208Mănescu DC, Tudor A, Mănescu AM, Mărgărit IR, Mănescu CO, Prisăcaru C et al. · 2026
- 209
- 210Bukowska B, Grzegorowska A, Szczerkowska-Majchrzak E, Bukowski K, Kadac-Czapska K, Grembecka M et al. · 2025
- 211Xu C, Cui X, Shi Y, Zhang T, Ni Z, Li K et al. · 2025
- 212Fallah Huseini H, Haghighi M, Kianbakht S, Ziaee M · 2025
- 213El Sayed S, Macri VI, Singh B, Segars JH, Islam MS · 2025
- 214Yin Y, Martínez R, Zhang W, Estévez M · 2024
- 215Dimitrijevic J, Tomovic M, Bradic J, Petrovic A, Jakovljevic V, Andjic M et al. · 2024
- 216Gawish AS, ElMofty MS, Jambi S, Felemban D, Ragheb YS, Elsayed SA · 2024
- 217Mohan M, C A M, D P, V AG · 2024
- 218Dogara AM, Hama HA, Ozdemir D · 2024
- 219Cherrada N, Chemsa AE, Gheraissa N, Laib I, Gueboudji Z, El-Shazly M et al. · 2024
- 220Piva A, Benvegnù G, Negri S, Commisso M, Ceccato S, Avesani L et al. · 2024
- 221Jang JY, Kim D, Im E, Kim ND · 2024
- 222Li H, Ruan J, Huang J, Yang D, Yu H, Wu Y et al. · 2023
- 223Zamanian MY, Sadeghi Ivraghi M, Khachatryan LG, Vadiyan DE, Bali HY, Golmohammadi M · 2023
- 224Mansoor K, Bardees R, Alkhawaja B, Mallah E, AbuQatouseh L, Schmidt M et al. · 2023
- 225Alami M, Boumezough K, Khalil A, Ramchoun M, Boulbaroud S, Fulop T et al. · 2023
- 226García-Villalba R, Tomás-Barberán FA, Iglesias-Aguirre CE, Giménez-Bastida JA, González-Sarrías A, Selma MV et al. · 2023
- 227Bauer-Büntzel C, Büntzel J, Zomorodbakhsch B, Keinki C · 2023
- 228Pomegranate (Punica granatum L.) Attenuates Neuroinflammation Involved in Neurodegenerative DiseasesMehdi A, Lamiae B, Samira B, Ramchoun M, Abdelouahed K, Tamas F et al. · 2022
- 229Saadat S, Beigoli S, Khazdair MR, Amin F, Boskabady MH · 2022
- 230
- 231Eghbali S, Askari SF, Avan R, Sahebkar A · 2021
- 232Hussein L, Gouda M, Buttar HS · 2021
- 233Hübner J, Mücke R, Micke O, Keinki C · 2021
- 234Amor AJ, Gómez-Guerrero C, Ortega E, Sala-Vila A, Lázaro I · 2020
- 235Livingstone TL, Beasy G, Mills RD, Plumb J, Needs PW, Mithen R et al. · 2019
- 236Basu A, Masek E, Ebersole JL · 2018
- 237Wang D, Özen C, Abu-Reidah IM, Chigurupati S, Patra JK, Horbanczuk JO et al. · 2018
- 238Basu A, Schell J, Scofield RH · 2018
- 239Bassiri-Jahromi S · 2018
- 240Sharma P, McClees SF, Afaq F · 2017
- 241Danesi F, Ferguson LR · 2017
- 242Shabbir MA, Khan MR, Saeed M, Pasha I, Khalil AA, Siraj N · 2017
- 243Paller CJ, Pantuck A, Carducci MA · 2017
- 244Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM · 2016
- 245Kim Y, Keogh JB, Clifton PM · 2016
- 246Turrini E, Ferruzzi L, Fimognari C · 2015
- 247
- 248Klempner SJ, Bubley G · 2012
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.